Medicare

Eli Lilly said Monday that some basic Medicare Part D plans could end up charging more than the touted $50 monthly out-of-pocket cap for its weight-loss drugs—a hitch in what had been one of the Biden administration’s marquee pledges around new obesity-drug coverage. Most plan options, according to Lilly, should still stick to the cap. Timing is key here: The U.S. Centers for Medicare and Medicaid Services has set out details for the Medicare GLP-1 Bridge, a temporary plan running from July 1 through Dec. 31, 2026. It will allow eligible Part D enrollees to access Zepbound or Wegovy for obesity with a $50 copay, before the wider BALANCE model comes online in 2027. GLP-1 drugs sit at the heart